Pau D'arco - Tabebuia impetiginosa - Tabebuia avellanedae

Taheebo has traditionally been used to treat a wide range of conditions, including bacterial infections, blood coagulation, cancer, and inflammatory diseases. However, there are no well-controlled clinical trials to support use of taheebo in these conditions.

Dosing

Clinical information is lacking to provide dosing recommendations for taheebo. In phase 1 and 2 clinical trials, the active component beta-lapachone (ARQ 501) was administered weekly at doses up to 450 mg/m2, either as monotherapy or in combination with various antineoplastic agents. Contraindications: Contraindications have not been identified.